121 related articles for article (PubMed ID: 11815521)
1. Improvement of asthma after administration of pioglitazone.
Hashimoto Y; Nakahara K
Diabetes Care; 2002 Feb; 25(2):401. PubMed ID: 11815521
[No Abstract] [Full Text] [Related]
2. FDA approves pioglitazone for diabetes.
Miller JL
Am J Health Syst Pharm; 1999 Sep; 56(17):1698. PubMed ID: 10512494
[No Abstract] [Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review.
Chilcott J; Wight J; Lloyd Jones M; Tappenden P
Health Technol Assess; 2001; 5(19):1-61. PubMed ID: 11701097
[No Abstract] [Full Text] [Related]
4. Pioglitazone: the future.
Brunetti P
Int J Clin Pract Suppl; 2001 Sep; (121):36. PubMed ID: 11594244
[No Abstract] [Full Text] [Related]
5. Effects of pioglitazone on diabetes-related outcomes in Hispanic patients.
Jun JK; Gong WC; Mathur R
Am J Health Syst Pharm; 2003 Mar; 60(5):469-73. PubMed ID: 12635453
[No Abstract] [Full Text] [Related]
6. Does hypertriglyceridemia present an indication for pioglitazone therapy in diabetes?
Kane JP
Diabetes Technol Ther; 2002; 4(2):153-5. PubMed ID: 12079618
[No Abstract] [Full Text] [Related]
7. Pioglitazone and rosiglitazone for diabetes.
Drug Ther Bull; 2001 Sep; 39(9):65-8. PubMed ID: 11586802
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic therapy for type 2 diabetes mellitus.
DeFronzo RA
Ann Intern Med; 2000 Jul; 133(1):73-4. PubMed ID: 10877745
[No Abstract] [Full Text] [Related]
9. Anticipated US approval for rosiglitazone and pioglitazone.
Diabetes Obes Metab; 1999 May; 1(3):181-2. PubMed ID: 11220298
[No Abstract] [Full Text] [Related]
10. The glitazones: proceed with caution.
Krische D
West J Med; 2000 Jul; 173(1):54-7. PubMed ID: 10903299
[No Abstract] [Full Text] [Related]
11. Cardiovascular risk reduction with pioglitazone.
Cardiovasc J S Afr; 2002; 13(4):218. PubMed ID: 12402932
[No Abstract] [Full Text] [Related]
12. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers.
Hofmann CA; Colca JR
Diabetes Care; 1992 Aug; 15(8):1075-8. PubMed ID: 1505314
[No Abstract] [Full Text] [Related]
13. Pioglitazone (Actos).
Med Lett Drugs Ther; 1999 Nov; 41(1066):112. PubMed ID: 10987011
[No Abstract] [Full Text] [Related]
14. A new era in type 2 diabetes mellitus treatment?
Laws A
Am J Med; 2001 Jul; 111(1):71-2. PubMed ID: 11448665
[No Abstract] [Full Text] [Related]
15. Marked improvement of glycaemic control with pioglitazone in a Type 2 diabetic patient associated with Charcot-Marie-Tooth disease.
Ota T; Osawa K
Diabet Med; 2003 May; 20(5):420-1. PubMed ID: 12752495
[No Abstract] [Full Text] [Related]
16. [Clinical efficacy of Pioglitazone (AD-4833)].
Kaneko T; Baba S
Nihon Rinsho; 1997 Nov; 55 Suppl():142-6. PubMed ID: 9434458
[No Abstract] [Full Text] [Related]
17. Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
Krentz AJ; Bailey CJ; Melander A
BMJ; 2000 Jul; 321(7256):252-3. PubMed ID: 10915108
[No Abstract] [Full Text] [Related]
18. [Pioglitazone].
Kobayashi M; Iwata M; Hiratani K
Nihon Rinsho; 2002 Sep; 60 Suppl 9():429-37. PubMed ID: 12387029
[No Abstract] [Full Text] [Related]
19. Actos (pioglitazone HCL) provides a safe, effective alternative for patients formerly taking Rezulin.
Diabetes Technol Ther; 2000; 2(2):290-1. PubMed ID: 11469274
[No Abstract] [Full Text] [Related]
20. The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients.
Baba T; Shimada K; Neugebauer S; Yamada D; Hashimoto S; Watanabe T
Diabetes Care; 2001 May; 24(5):953-4. PubMed ID: 11347762
[No Abstract] [Full Text] [Related]
[Next] [New Search]
